Methemoglobinemia Clinical Trial
Official title:
Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine
To establish and compare maximum methemoglobin blood levels and times to maximum methemoglobin blood levels following the administration of the injectable local anesthetics prilocaine and lidocaine when used for dental treatment in pediatric patients under general anesthesia. Patients will be randomized into three equal study groups. Two of the study groups will receive local anesthetic and the third group will not. Methemoglobin blood levels will be non-invasively monitored and recorded throughout dental treatment for all groups using a Masimo Radical-7 Pulse Co-Oximeter device.
Methemoglobin is an abnormal hemoglobin that is formed by the oxidation of one or more of
the four heme groups of hemoglobin by oxygen and other exogenous oxidizing agents. The
injectable local anesthetic prilocaine that is routinely used in the medical and dental
professions is a well known inducer of methemoglobin. The injectable local anesthetic
lidocaine has also been suggested to be associated with the development of methemoglobin;
however, there is no direct evidence supporting these claims.
The concern with methemoglobin is that it is a dose-dependent toxin. The oxidation of one of
the iron groups from a ferrous state to a ferric state alters the molecular structure of the
hemoglobin molecule and impairs its ability to bind oxygen. This ultimately results in less
oxygen being delivered to peripheral tissues and less carbon dioxide being removed which can
cause tissue hypoxia. A small amount (0-2%) of methemoglobin is normally present in the
blood as a result of the oxidation of hemoglobin by the prototypical oxidant oxygen.
However, when an individual is exposed to an exogenous oxidizing agent of sufficient dosage
and potency, methemoglobin levels can rise above 2% and a person can develop what is known
as acquired methemoglobinemia. Signs of cyanosis as a result of acquired methemoglobinemia
usually become present when methemoglobin blood levels rise above 15%.
Despite the injectable local anesthetic prilocaine being a well known inducer of
methemoglobin and lidocaine being a speculated inducer, there are no documented studies or
trials in the dental literature as to the extent of the amount of methemoglobin that is
formed following the routine use of these injectable local anesthetics.
This investigation will examine the peak blood levels of methemoglobin and the time to the
peak levels of methemoglobin following the use of injectable prilocaine and lidocaine when
used for dental treatment in pediatric patients under general anesthesia.
This study population will consist of 90 patients, 3 to 6 years of age, scheduled to undergo
comprehensive dental rehabilitation under general anesthesia at the Koppel Special Care
Dentistry Center at Loma Linda University School of Dentistry. Following enrollment,
subjects will be randomized into three equal study groups: 1) 4% prilocaine plain, 2) 2%
lidocaine with 1:100,000 epinephrine, and 3) No local anesthetic. All subjects will have a
Masimo Radical-7 pediatric, non-disposable, pulse co-oximeter sensor placed on the ring
finger of the right hand following the induction of general anesthesia. The sensor will then
be connected to a Radical-7 Pulse Co-Oximeter. The pulse co-oximeter will non-invasively
monitor and record methemoglobin blood levels at 10 second intervals throughout dental
treatment. Following a routine oral examination, radiographs, and prophylaxis, subjects
assigned to Groups 1 and 2 will be administered local anesthetic for restorative dental
treatment. Group 1 subjects will receive 5mg/kg of 4% prilocaine plain and Group 2 subjects
will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine. Group 3 subjects will not
receive local anesthetic. The time of local anesthetic administration and baseline
methemoglobin blood levels will be recorded. Methemoglobin blood levels will be monitored
and recorded throughout the completion of the dental treatment and during recovery from
general anesthesia until subject movement precludes any further monitoring.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02493283 -
Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration
|
Phase 1 | |
Completed |
NCT02478281 -
Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults
|
Phase 1 | |
Completed |
NCT03542760 -
Acquired Methemoglobinemia Observational Registry
|
||
Active, not recruiting |
NCT00960050 -
Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone
|
Phase 1 | |
Completed |
NCT00993694 -
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
|
N/A | |
Completed |
NCT01766999 -
Methemoglobinemia After Liposuction - Diagnostic by Pulse Oximetry and Blood Gas Analysis.
|